secwatch.observer — SEC 8-K summary
======================================

Issuer:     Applied Therapeutics, Inc. (—)
CIK:        0001697532
Form:       8-K
Filed at:   2023-11-17T23:59:59+00:00
Accession:  0001104659-23-119514
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Applied Therapeutics appoints Les Funtleyder as CFO effective Nov 20, 2023
--------------------------------------------------------------------------

- Funtleyder receives $525k base salary, 40% target bonus, and 300,000 RSUs vesting over 2 years.
- Catherine Thorpe ceases as interim principal financial officer; remains Chief Accounting Officer.
- Severance includes 3 months base salary, 3 months COBRA, prorated bonus, and full equity vesting upon qualifying termination.
- Good reason for resignation defined as >10% salary cut, material duty reduction, or relocation >50 miles.
- Employment at-will; cause defined as felony, fraud, material breach of duties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1697532/000110465923119514/0001104659-23-119514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1697532/000110465923119514/tm2331016d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-119514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer